Product Description: Dehydrojuncusol, a potent HCV inhibitor, targets HCV NS5A and is able to inhibit RNA replication of replicons harboring resistance mutations to anti-NS5A direct-acting antivirals. Dehydrojuncusol significantly inhibits HCV infection when added after virus inoculation of HCV genotype 2a (EC50=1.35 µM)[1].
Applications: COVID-19-anti-virus
Formula: C18H16O2
References: [1]Sahuc ME, et al. Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from Juncus maritimus, Is a New Inhibitor of Hepatitis C Virus RNA Replication. J Virol. 2019;93(10):e02009-18. Published 2019 May 1.
CAS Number: 117824-04-1
Molecular Weight: 264.32
Research Area: Infection
Solubility: 10 mM in DMSO
Target: HCV;HCV Protease